Some of these products are not FDA cleared. Please contact your sales representative for more information.
Product claims may differ from country to country based on regulations and product approvals.
Please contact your country representative for further details.
Subscribe to our e-mail newsletter to get our latest news and dates by e-mail
Subscribe / Unsubscribe
Participants came from 11 different countries and made the workshop a truly international event with well renowned speakers and also ample time and space for informal exchange. It was the 8th time B·R·A·H·M·S organized the Forum on thyroid diseases.
The spectrum of topics ranged from recent findings on the molecular basis and screening strategies to diagnosis and therapy of thyroid cancer. The Forum was headed by Prof. Josef Köhrle, Director of the Institute of Experimental Endocrinology, Charité University Medicine Berlin, und Dr. Petros Perros, Endocrine Unit, Freeman Hospital, Newcastle England.
At the beginning Prof. Laurence Leenhardt, Paris, presented recent data on thyroid cancer. Prof. Massimo Santoro, Naples Italy, explained the consequences of new findings on a molecular basis for diagnosis and therapy. Classifying thyroid tumors is a big challenge for pathologists. Prof. Kurt Werner Schmid, Essen Germany, provided an insight into this issue. Prof. Rosella Elisei, Pisa Italy, gave a presentation on screening strategies for medullary thyroid cancer. This hereditary form of thyroid cancer appears at an earlier age and grows aggressively. Therefore, timely identification of risk groups is crucial for early detection and therapy success. Prof. J. W. A. Smit, Leiden Netherlands, was discussing strenghts and weaknesses of several guidelines on diagnosis and treatment of thyroid cancer. Prof. Barbara Jarzab, Gliwice Poland, gave an outlook on future challenges in thyroid cancer research. At the end the participants all together discussed an unusual case that was presented by the endocrine practitioner Dr. Reinhard Finke, Berlin.
B·R·A·H·M·S offers the assays B·R·A·H·M·S Tg-S RIA, B·R·A·H·M·S Tg-pluS RIA, B·R·A·H·M·S Tg-pluS LIA, B·R·A·H·M·S Calcitonin RIA, B·R·A·H·M·S PCT and B·R·A·H·M·S hTg KRYPTOR in regards to thyroid cancer treatment control and diagnosis.
You can find speakers abstracts and additional information on the B·R·A·H·M·S-Forum here for download.